Mark L. Fuerst

“Many physicians are trying out Threads, and we already connect on LinkedIn, like many other professionals.” 

SYD985 may provide a new treatment option for patients with previously treated locally advanced or metastatic HER2-positive metastatic breast cancer.

The overall survival benefit with ribociclib increased over time.

The checkpoint inhibitor cemiplimab improved survival in patients with recurrent/metastatic cervical carcinoma compared with single-agent chemotherapy.

Median OS was not reached for the T-VEC plus pembrolizumab arm and 49.2 months for the placebo plus pembrolizumab arm.

There was no improvement in overall survival with bevacizumab.